Pseudomyxoma pleurii: unusual location of a rare disease
Radiology Case Reports, 2021 Pseudomyxoma peritonei with pleural extension is very rare. Dissemination in the pleural cavity can be trans diaphragmatic or hematogenous. Appendicular and ovarian mucinous tumors are the most often involved.
Kaoutar Imrani +4 more
doaj
Pseudomyxoma peritonei – a revisit: report of 2 cases and literature review [PDF]
, 2006 BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare, chronic, relapsing, diagnostically challenging and poorly understood disease characterized by disseminated mucinous ascites and peritoneal implants.
Kanthan, Rani +2 more
core +3 more sources
Frontiers in Oncology, 2022 BackgroundPseudomyxoma peritonei is a rare disease that presents as a malignant tumor on the peritoneal surface. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the standard treatment for this disease and frequently ...
Xiaoyun Gao +9 more
doaj +1 more source
South African Journal of Radiology, 2014 Pseudomyxoma peritonei is a rare complication of mucinous tumours of appendiceal or ovarian origin. Other associations are malignancies of the colon, urachus and biliary tree.
Binit Sureka +4 more
doaj +1 more source
Pseudomyxoma Peritonei in a Patient with History of Breast Cancer
The Korean Journal of Gastroenterology, 2016 Pseudomyxoma peritonei is a very rare condition, and even rarer in patients with history of cancer. A 70-year old woman with a history of breast cancer was admitted with abdominal pain and distention.
Tae Seob Jung +6 more
doaj +1 more source
CHALLENGES IN CHOICE OF THE TREATMENT STRATEGY FOR PATIENTS WITH RECURRENT PSEUDOMYXOMA PERITONEI
Сибирский онкологический журнал, 2019 Pseudomixoma peritonei is a rare type of peritoneal carcinomatosis accompanied by accumulation of mucus and high recurrence rate and in some cases complicated with intestinal obstruction.
A. G. Abdullaev +2 more
doaj +1 more source
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. [PDF]
, 2022 Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival is possible. Complete cytoreductive surgery (CRS) together with combination immunochemotherapy is essential to achieve cure. Hyperthermic intraperitoneal chemotherapy (
Adamina, M. +16 more
core +5 more sources
Cytoreductive surgery alone or combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei [PDF]
, 2018 This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The aim of this work is to evaluate the efficacy of cytoreductive surgery alone versus cytoreductive surgery in combination with hyperthermic intraperitoneal ...
Ma, Huaixing +7 more
core +1 more source
Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review [PDF]
, 2022 The objective of this systematic review is to provide efficacy and safety data in the application of Intra-Abdominal Hyperthermia Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) in patients with Peritoneal Pseudomyxoma (PMP) of origin in the cecal ...
Bernardo, Wanderley Marques +4 more
core +2 more sources
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin - 801 Cases from a Single Institution in China [PDF]
, 2020 Aim: As more and more centers has published their treatment results ofpseudomyxoma peritonei (PMP) with cytoreductive surgery (CRS) andhyperthermic intraperitoneal chemotherapy (HIPEC), the data from Chinais missing.
An, Lubiao +10 more
core +2 more sources